|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | A61K 31/401 | |
| A61P 25/08 |
| (11) | Patento numeris | 2117535 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 08708027.1 |
| Europos patento paraiškos padavimo data | 2008-01-21 | |
| (97) | Europos patento paraiškos paskelbimo data | 2009-11-18 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2011-10-26 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/EP2008/050623 |
| Data | 2008-01-21 |
| (87) | Numeris | WO 2008/090116 |
| Data | 2008-07-31 |
| (30) | Numeris | Data | Šalis |
| 0701365 | 2007-01-24 | GB |
| (72) |
ALVARO, Giuseppe, IT
LARGE, Charles, IT
|
| (73) |
Glaxo Group Limited,
Glaxo Wellcome House Berkeley Avenue, Greenford, Middlesex UB6 0NN,
GB
|
| (54) | PHARMACEUTICAL COMPOSITIONS COMPRISING NK1 RECEPTOR ANTAGONISTS AND SODIUM CHANNEL BLOCKERS |
| PHARMACEUTICAL COMPOSITIONS COMPRISING NK1 RECEPTOR ANTAGONISTS AND SODIUM CHANNEL BLOCKERS |